Marker Therapeutics Inc (MRKR NASDAQ) stock market data APIs
$0.9456
0.05(5.3%)
as of September 17, 2025
Try our APIs with
free plan!
Marker Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
Prev. Close
0.9456
Open
0.9926
High
1.0168
Low
0.944
52 wk Range
0.8099-5.95
Market Cap
12 872 K
Shares Outstanding
12 939 K
Revenue
5 388 K
EPS
-0.29
Beta
1.522
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Marker Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Marker Therapeutics Inc data using free add-ons & libraries
Get Marker Therapeutics Inc Fundamental Data
Marker Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 388 K
- EBITDA: -11 792 272
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Marker Therapeutics Inc News
New
Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Tuesday's pre-market session: top gainers and losers
Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVV...
Marker's lymphoma therapy shows promising response rates in trial
HOUSTON - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage biotech company with a market capitalization of $16.3 million, reported Tuesday that its Phase 1 APOLLO study of MT-601 therapy demo...
Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
